Drug intelligence / Profile preview

ramipril + indapamide

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Ramipril + indapamide is a fixed-dose combination pharmaceutical composition used for the treatment of hypertension. It combines two antihypertensive agents with complementary mechanisms of action: ramipril, an angiotensin-converting enzyme (ACE) inhibitor, and indapamide, a thiazide-like diuretic. Ramipril works by inhibiting the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, thereby reducing peripheral vascular resistance and aldosterone secretion. Indapamide acts primarily on the distal convoluted tubules of the kidney to inhibit the sodium-chloride symporter, promoting the excretion of sodium and water and reducing peripheral vascular resistance through a direct vasodilatory effect. This combination is particularly effective for patients whose blood pressure is not adequately controlled by monotherapy, providing synergistic blood pressure reduction and potentially reducing the risk of cardiovascular events such as stroke and myocardial infarction.

Brand names
Pramind
Other names
Ramipril/Indapamide
02

Targets

ACE (Angiotensin Converting Enzyme)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)

Beyond the preview

Go deeper on ramipril + indapamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ramipril + indapamide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call